GPCM
KIN

Granite Point Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Granite Point Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-317,929
Closed -$1.58M – 215
2021
Q1 		$1.58M Buy
+317,929
New +$1.54M 0.06% 111

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Granite Point Capital Management's KIN Position: Q2 2021 in Review

Granite Point Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 317,929 shares — an estimated $1.58M sold.

Granite Point Capital Management first reported a position in KIN in Q1 2021 and held it in 1 quarter. The position peaked at $1.58M in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • Granite Point Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 317,929 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $1.58M.
  • Granite Point Capital Management first reported a position in Kindred Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Granite Point Capital Management's Kindred Biosciences, Inc. position peaked at $1.58M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Granite Point Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.